TD Cowen analyst Joseph Thome lowered the firm’s price target on PTC Therapeutics (PTCT) to $50 from $56 and keeps a Hold rating on the shares after the FDA issued a complete response letter for vatiquinone in Friedreich’s ataxia. The firm removed Friedreich’s ataxia from its model and believes a a second successful Phase III study will likely be required for approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Receives FDA Complete Response Letter
- PTC Therapeutics receives Complete Response Letter for vatiquinone NDA
- PTC Therapeutics’ Earnings Call Highlights Sephience Success
- PTC Therapeutics price target lowered to $70 from $72 at Baird
- PTC Therapeutics price target raised to $56 from $52 at TD Cowen